EvolusEOLS -3.50%68 ROC (Joel Greenblatt) % is -79.79% as of Mar. 2026. GuruFocus rates EOLS with a GF Score™ of 68/100 and a GF Value™ of $13.67 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 983 Drug Manufacturers companies, Evolus ranks worse than 87.59% on this metric.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Evolus's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -79.79%.
The historical rank and industry rank for Evolus's ROC (Joel Greenblatt) % or its related term are showing as below:
EOLS'
s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -3149.12 Med: -994.62 Max: -74.03
Current: -74.03
During the past 11 years, Evolus's highest ROC (Joel Greenblatt) % was -74.03%. The lowest was -3149.12%. And the median was -994.62%.
EOLS's ROC (Joel Greenblatt) % is ranked worse than 87.59% of 983
companies
in the Drug Manufacturers industry
Industry Median: 11.46
vs EOLS: -74.03
Evolus's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 43.90% per year.
The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.
The historical data trend for Evolus's ROC (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EOLS vs NIKA, EBS, ELTP: ROC (Joel Greenblatt) % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Evolus's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Evolus ROC (Joel Greenblatt) % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Evolus's ROC (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Evolus's ROC (Joel Greenblatt) % falls into.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:
EBIT stands for Earnings Before Interest and Taxes.
Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.
GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.
Note:
The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROC (Joel Greenblatt) % of -79.79% mean?
Evolus (EOLS) has a ROC (Joel Greenblatt) % of -79.79% as of Mar. 2026. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Evolus and its competitors. According to the industry distribution chart, Evolus ranks #861 out of 983 companies in the Drug Manufacturers industry, placing it in the top 87.6%.
Is Evolus' ROC (Joel Greenblatt) % too high?
Evolus' current ROC (Joel Greenblatt) % is -79.79%. Based on the distribution chart, Evolus ranks #861 out of 983 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Evolus has a GF Score™ of 68/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Evolus' ROC (Joel Greenblatt) % compare to NIKA and EBS?
According to the Drug Manufacturers industry distribution chart, Evolus ranks #861 out of 983 companies for ROC (Joel Greenblatt) %. This places Evolus in the lower half of its industry. The industry median ROC (Joel Greenblatt) % is 11.46. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Drug Manufacturers company?
The median ROC (Joel Greenblatt) % among Drug Manufacturers companies is 11.46, based on 983 companies in the industry. Companies in the top quartile (top 25%) have a ROC (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Evolus and its competitors. For the Drug Manufacturers industry, the median ROC (Joel Greenblatt) % is 11.46 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Evolus's current ROC (Joel Greenblatt) % is -79.79%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Evolus stock overvalued right now?
Based on GuruFocus' analysis, Evolus (EOLS) is currently considered Possible Value Trap. The stock's GF Value™ is $13.67, compared to a current price of $6.61 — trading 51.6% below its estimated fair value. The current ROC (Joel Greenblatt) % is -79.79%. Evolus' overall GF Score™ is 68/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For Evolus (EOLS), the current ROC (Joel Greenblatt) % is -79.79% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Evolus (EOLS) Overvalued in 2026?
Based on GuruFocus' analysis, Evolus stock appears to be undervalued.
The current stock price of $6.61 is trading 51.6% below its estimated GF Value™ of $13.67.
GuruFocus considers Evolus to be Possible Value Trap.
Key valuation signals for EOLS:
ROC (Joel Greenblatt) %: -79.79%
GF Value™: $13.67 vs. price of $6.61 (51.6% below fair value)
No single metric tells the full story. See the EOLS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Evolus Inc is a performance beauty company offering medical aesthetic products in the cash-pay aesthetic market. The company's commercially available products represent two product categories within medical aesthetics: injectable neurotoxins and injectable hyaluronic acid (HA) gels. Its commercial products are: Jeuveau, a proprietary 900-kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe frown lines, in adults; and Evolysse, a collection of injectable HA gels that utilizes first-generation cold technology. The line includes several products, including mid face, nasolabial folds, lips, and eyes. Geographically, the company currently has operations in the United States, Canada, Europe, and Australia.
68GF Score
Get the complete analysis for EOLS
ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
EOLS has been successfully added to your 
